De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Condition:   Graft-versus-host Disease Interventions:   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Ruxolitinib Sponsor:   Medical College of Wisconsin Not yet recruiting

Source: ClinicalTrials.gov - November 18, 2022 Category: Research Source Type: clinical trials